Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PARP inhibitors: enhancing efficacy through rational combinations.
Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. Bhamidipati D, et al. Among authors: yap ta. Br J Cancer. 2023 Oct;129(6):904-916. doi: 10.1038/s41416-023-02326-7. Epub 2023 Jul 10. Br J Cancer. 2023. PMID: 37430137 Free PMC article. Review.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Knisely A, et al. Among authors: yap ta. Cancer. 2024 Feb 1;130(3):400-409. doi: 10.1002/cncr.35063. Epub 2023 Oct 21. Cancer. 2024. PMID: 37864520 Clinical Trial.
Targeting ATR in Cancer Medicine.
Salguero C, Valladolid C, Robinson HMR, Smith GCM, Yap TA. Salguero C, et al. Among authors: yap ta. Cancer Treat Res. 2023;186:239-283. doi: 10.1007/978-3-031-30065-3_14. Cancer Treat Res. 2023. PMID: 37978140
Targeting ATR in patients with cancer.
Ngoi NYL, Pilié PG, McGrail DJ, Zimmermann M, Schlacher K, Yap TA. Ngoi NYL, et al. Among authors: yap ta. Nat Rev Clin Oncol. 2024 Apr;21(4):278-293. doi: 10.1038/s41571-024-00863-5. Epub 2024 Feb 20. Nat Rev Clin Oncol. 2024. PMID: 38378898 Review.
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.
Pilié PG, Giuliani V, Wang WL, McGrail DJ, Bristow CA, Ngoi NYL, Kyewalabye K, Wani KM, Le H, Campbell E, Sanchez NS, Yang D, Gheeya JS, Goswamy RV, Holla V, Shaw KR, Meric-Bernstam F, Liu CY, Ma X, Feng N, Machado AA, Bardenhagen JP, Vellano CP, Marszalek JR, Rajendra E, Piscitello D, Johnson TI, Likhatcheva M, Elinati E, Majithiya J, Neves J, Grinkevich V, Ranzani M, Luzarraga MR, Boursier M, Armstrong L, Geo L, Lillo G, Tse WY, Lazar AJ, Kopetz SE, Geck Do MK, Lively S, Johnson MG, Robinson HMR, Smith GCM, Carroll CL, Di Francesco ME, Jones P, Heffernan TP, Yap TA. Pilié PG, et al. Among authors: yap ta. Clin Cancer Res. 2024 May 15;30(10):2121-2139. doi: 10.1158/1078-0432.CCR-23-1763. Clin Cancer Res. 2024. PMID: 38416404 Free PMC article.
BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.
Lei G, Mao C, Horbath AD, Yan Y, Cai S, Yao J, Jiang Y, Sun M, Liu X, Cheng J, Xu Z, Lee H, Li Q, Lu Z, Zhuang L, Chen MK, Alapati A, Yap TA, Hung MC, You MJ, Piwnica-Worms H, Gan B. Lei G, et al. Among authors: yap ta. Cancer Discov. 2024 Aug 2;14(8):1476-1495. doi: 10.1158/2159-8290.CD-23-1220. Cancer Discov. 2024. PMID: 38552003
UBA1 inhibition sensitizes cancer cells to PARP inhibitors.
Awasthi S, Dobrolecki LE, Sallas C, Zhang X, Li Y, Khazaei S, Ghosh S, Jeter CR, Liu J, Mills GB, Westin SN, Lewis MT, Peng W, Sood AK, Yap TA, Yi SS, McGrail DJ, Sahni N. Awasthi S, et al. Among authors: yap ta. Cell Rep Med. 2024 Dec 17;5(12):101834. doi: 10.1016/j.xcrm.2024.101834. Epub 2024 Dec 2. Cell Rep Med. 2024. PMID: 39626673 Free article.
249 results